Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China
第一作者机构:[1]Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China[2]Shanghai Geriatr, Med Ctr, Dept Hematol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Wang Wenjing,Li Jing,Li Mengyuan,et al.Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China[J].BLOOD.2024,144:5159-5160.doi:10.1182/blood-2024-207888.
APA:
Wang, Wenjing,Li, Jing,Li, Mengyuan,He, Xiao,Bao, Li...&Liu, Peng.(2024).Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China.BLOOD,144,
MLA:
Wang, Wenjing,et al."Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China".BLOOD 144.(2024):5159-5160